Hydroxychloroquine is used for patients with systemic/cutaneous lupus erythematosus or Sjogren's syndrome who have annular erythema on the face and/or trunk as a first choice in most countries other than Japan. In this study, we will evaluate the efficacy and safety of hydroxychloroquine for Japanese systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunk.

Hydroxychloroquine 200 mg will be administrated once daily. If insufficient, dosage can be escalated to 400 mg twice daily, but not exceed 6.5 mg/kg/day.

Interventions/Control_2

Interventions/Control_3

Interventions/Control_4

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Eligibility

Age-lower limit

20

years-old

<=

Age-upper limit

75

years-old

>

Gender

Male and Female

Key inclusion criteria

1. Patients with systemic/cutaneous lupus erythematosus or Sjogren's syndrome who have annular erythema on the face and/or trunk that are resistant to steroid and/or tacrolimus treatment for external use.
2. Patients without retinopathy examined by ophthalmologist.

Key exclusion criteria

1. Patients with current or previous history of retinopathy.
2. Patients unable to take or unsupplied with 4-aminoquinoline.
3. Body weight is less than 30 Kg.
4. History of pregnancy or lactation.
5. Other patients who were judged to be ineligible for the study by an attending physician.